Matches in Wikidata for { <http://www.wikidata.org/entity/Q104288998> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- Q104288998 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 9ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104288998 description "article scientifique publié en 2020" @default.
- Q104288998 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104288998 description "scientific article published on 09 December 2020" @default.
- Q104288998 description "wetenschappelijk artikel" @default.
- Q104288998 description "наукова стаття, опублікована 9 грудня 2020" @default.
- Q104288998 name "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 name "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 name "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 type Item @default.
- Q104288998 label "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 label "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 label "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 prefLabel "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 prefLabel "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 prefLabel "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 P1433 Q104288998-425236AD-47DD-4B3B-AF20-E30399B387D3 @default.
- Q104288998 P1476 Q104288998-C9B74E83-A99D-4F78-B13B-6A4AC9BDC36D @default.
- Q104288998 P2093 Q104288998-1DF4915D-6AC8-4FFC-91CC-F5AA4F039D1F @default.
- Q104288998 P2093 Q104288998-4F3C3956-EC7E-4ABC-88AC-24B00E28DC72 @default.
- Q104288998 P2093 Q104288998-D7212BBB-1444-4364-A875-8E17E5739BDD @default.
- Q104288998 P31 Q104288998-F087A495-BA11-4946-B0A0-34C44228EF4F @default.
- Q104288998 P356 Q104288998-6860F325-AB05-4B90-ACF0-0B04E4DAAB45 @default.
- Q104288998 P577 Q104288998-8E3132E4-280F-48A1-8398-0689E59061D3 @default.
- Q104288998 P698 Q104288998-63E7D3F4-B2B7-4337-98D3-8CE82B32636D @default.
- Q104288998 P356 J.JHEP.2020.11.031 @default.
- Q104288998 P698 33309116 @default.
- Q104288998 P1433 Q15724402 @default.
- Q104288998 P1476 "Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"" @default.
- Q104288998 P2093 "Ansgar W Lohse" @default.
- Q104288998 P2093 "Marcial Sebode" @default.
- Q104288998 P2093 "Mette Vesterhus" @default.
- Q104288998 P31 Q13442814 @default.
- Q104288998 P356 "10.1016/J.JHEP.2020.11.031" @default.
- Q104288998 P577 "2020-12-09T00:00:00Z" @default.
- Q104288998 P698 "33309116" @default.